Form of Award NoticeAmgen Inc • May 8th, 2012 • Biological products, (no disgnostic substances) • Delaware
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made of part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
Form of Award NoticeAmgen Inc • May 8th, 2012 • Biological products, (no disgnostic substances)
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made of part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
Form of Award NoticeAmgen Inc • May 8th, 2012 • Biological products, (no disgnostic substances) • Delaware
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made of part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND ASTRAZENECA COLLABORATION VENTURES, LLCCollaboration Agreement • May 8th, 2012 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Collaboration Agreement (this “Agreement”) is entered into as of the 30th day of March, 2012 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and AstraZeneca Collaboration Ventures, LLC, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (“Partner”). Amgen and Partner are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (“AstraZeneca”), [*] is a party to this Agreement [*].
Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799Amgen Inc • May 8th, 2012 • Biological products, (no disgnostic substances)
On behalf of Amgen Inc., I am pleased to confirm the following amendment to your Consulting Services Agreement of February 1, 2011 (the “Agreement”).
